News Briefing channel feed

Uni­corn Mod­er­na joins line­up to list on Hong Kong's ex­change; Proces­sa li­cens­es com­pound from Con­cert

8 years ago

Pro­teosta­sis pulls stock of­fer­ing fol­low­ing Ker­ris­dale short re­port; Cidara is­sues sup­ple­men­tal PhII reza­fun­gin da­ta

8 years ago

GSK launch­es PhI­II lu­pus com­bo study with Benlysta/rit­ux­imab; Ci­pher snatch­es Cana­di­an drug port­fo­lio from Car­diome

8 years ago

Ho­mol­o­gy, Unum set IPO terms; Knight pays Arde­lyx $19M for tena­panor rights in Cana­da

8 years ago

No­var­tis CEO Vas Narasimhan: We can do bet­ter at R&D, but we need FDA’s help; J&J gets $2.1B bid for LifeS­can

8 years ago

Lon­car In­vest­ments launch­es Chi­na bio­phar­ma in­dex; La Jol­la prices $100M pub­lic of­fer­ing

8 years ago

PureTech Health snags $100M to fund af­fil­i­ates; PolyPid takes a third stab at IPO

8 years ago

FDA gives pri­or­i­ty re­view to new Keytru­da sBLA; As­traZeneca's Pearl signs asth­ma de­vel­op­ment pact with Avil­lion

8 years ago

As­traZeneca push­es back OS read­out on MYS­TIC to H2; An­thera shares oblit­er­at­ed in re­peat PhI­II flop

8 years ago

Nim­bus found­ing CSO Rosana Kapeller leaves to ex­plore ex­ec role; AI start­up BioX­cel pock­ets $60M from IPO

8 years ago

#MeToo: ex-Sanofi em­ploy­ee gets un­fair dis­missal law­suit tossed, Ap­tose inks $125M BET in­hibitor deal

8 years ago

Jakobovits abrupt­ly ex­its Adicet; Stan­ford re­searchers un­cov­er mech­a­nis­tic de­tails of ALS us­ing CRISPR

8 years ago

Ar­cus to raise $99M IPO; Van­da wants mar­ket­ing ap­proval for jet lag

8 years ago

Per­lara col­lab­o­rates with Har­vard/Un­di­ag­nosed Dis­eases Net­work; Verona shares soar on pos­i­tive CF da­ta

8 years ago

With Resta­sis in its crosshairs, My­lan adds a Botox biosim with Re­vance; Ver­tex starts sec­ond PhI­II triple com­bo CF study

8 years ago

Scopia snags two board seats at Acor­da fol­low­ing stock pur­chase; BeiGene nabs sec­ond in­di­ca­tion for Revlim­id in Chi­na

8 years ago

Ex­elix­is/Dai­ichi Sankyo ask Japan­ese reg­u­la­tors for green light on hy­per­ten­sion drug; Bris­tol-My­ers Squibb li­cens­es GPCR tech from Do­main Ther­a­peu­tics

8 years ago

Glob­al syn­di­cate backs Prokar­i­um's $10M round; Bavar­i­an Nordic to test can­cer vac­cine with Imfinzi; AI start­up buys drug de­vel­op­ment fa­cil­i­ty

8 years ago

FDA of­fers quick re­view for Shire's prospec­tive block­buster lanadelum­ab; Big Phar­ma loves big buy­backs

8 years ago

Evelo Bio rais­es $47.5M for I/O work; Ver­tex gets start­ed on a fast piv­otal ef­fort for triple CF com­bo

8 years ago

Ex-HHS Sec­re­tary Tom­my Thomp­son adds an­oth­er biotech to his re­sume; Medi­gene OK'd for first TCR clin­i­cal tri­al

8 years ago

Acor­da gets a bad­ly need­ed PDU­FA date with the FDA on Parkin­son's drug; Take­da signs neu­ro­log­i­cal col­lab­o­ra­tion with an­ti­sense play­er Wave Life Sci­ences

8 years ago

Roivant Sci­ences in ex­clu­sive joint ven­ture talks with Ar­bu­tus; DBV gets green light to sub­mit peanut al­ler­gy patch

8 years ago

Ar­a­digm los­es CEO, CMO and CFO fol­low­ing reg­u­la­to­ry dis­as­ter; Omeros shares go up on pos­i­tive re­sults for blood clot treat­ment

8 years ago
First page Previous page 61626364656667 Next page Last page
A service from the Financial Times